Close menu




November 18th, 2025 | 07:10 CET

Takeover fever! LAURION Mineral Exploration, Evotec, and Mutares are tempting investors to get on board!

  • Mining
  • Commodities
  • Gold
  • Defense
  • Biotechnology
Photo credits: pixabay.com

M&A – mergers and acquisitions - remain powerful performance drivers for shareholders of potential takeover targets. But companies that acquire others also benefit from increased growth, access to new markets and technologies, and cost synergies. According to a recent study by Bain & Company, the majority of M&A activity in the current year, amounting to around USD 265 billion, has taken place in the energy and commodities sectors. In healthcare and life sciences, deals with a volume of USD 107 billion were recorded. So who could the next takeover candidates be?

time to read: 3 minutes | Author: Carsten Mainitz
ISIN: LAURION MINERAL EXPLORATION INC | CA5193221010 , EVOTEC SE INH O.N. | DE0005664809 , MUTARES KGAA NA O.N. | DE000A2NB650

Table of contents:


    LAURION Mineral Exploration – A guarantee for shareholder value

    Gold prices of over USD 4,000 per ounce, a sustained long-term upward trend in the precious metal, and the coffers of the major players bulging with cash for acquisitions already provide an excellent backdrop for LAURION Mineral Exploration. The Company is advancing the Ishkōday Gold and Base Metal Project in the Canadian province of Ontario.

    The 57.43 sq km project is located 220 km northeast of Thunder Bay in the resource-rich Beardmore-Geraldton Greenstone Belt. Ishkōday hosts gold, silver, zinc, and copper mineralization along a 6 x 2.5 km corridor. To date, nearly 100,000 meters in 462 holes have been drilled, including multiple very high-grade intercepts. Outstanding results were achieved as part of the 7,000-meter 2025 summer drill program. In the Cyril Knight Showing Zone, a whopping 32.47 g/t gold was detected over 1.90 m, including 0.90 m grading 67.80 g/t gold.

    Recent drill results indicate the mineralized zone of the historical Brenbar Mine Area may extend further to the north and northeast. The evaluation confirms that mineralization continues both in the targeted areas and at depth.

    The Company will continue to explore the Ishkōday Project in the coming year and plans to drill 7,000 to 10,000 meters. With further progress and new data confirming the high-grade mineralization, expanding or better defining it, the stock is gradually moving up the list of potential takeover candidates - a scenario that management openly keeps in view. The fact that "family and friends" hold nearly three-quarters of the shares guarantees that only measures that increase shareholder value will be taken. Despite its progress, the stock remains under the radar for many investors. A first step to broaden visibility was the recent Frankfurt listing at the end of October. Based on a share price of CAD 0.30, LAURION currently carries a valuation of around CAD 80 million.

    Evotec – Insiders buying again

    Evotec is a recognized heavyweight in the biotech sector. The Company's core strength lies in the systematic discovery and early development of new active ingredients based on a technology-driven, scalable platform. This model makes its services highly attractive to major pharmaceutical companies – Evotec collaborates with all leading global players – as well as to more than 800 biotech firms and numerous academic institutions.

    Disappointing operating developments due to weak demand in the market for early-stage drug research have been putting pressure on the share price for months. Management is attempting to counter the negative trend with strategic adjustments and cost savings, but these measures have not yet borne fruit. The share price has successfully tested the support level of EUR 5 for the second time this year.

    Most recently, both the Management Board and Supervisory Board purchased treasury shares. With its current service portfolio and a market capitalization of around EUR 900 million, Evotec is definitely a takeover candidate. Analysts place the average price target at just over EUR 9, giving the share a price potential of over 70% over a 12-month horizon.

    Mutares – Upside of over 50% and generous dividends

    Mutares makes its money from buying and selling corporate investments. The private equity holding company, with 15 regional offices worldwide, buys companies in transition that show significant potential for operational improvement and sells them again after stabilization and repositioning. A few days ago, the Company delighted market participants with positive quarterly figures.

    The fact that Mutares expects further transactions before the end of the year certainly also had a positive effect. It can therefore be safely assumed that the Company will achieve its annual targets. Next summer, shareholders can once again look forward to a generous dividend. Last year, this stood at EUR 2, which is also likely to be the new minimum target. The share price is expected to quickly recover from the current dip caused by the profit warning from Steyr Motors. Analysts estimate the share price potential at over 50%! The dividend yield is over 7%.


    There are many ways for shareholders to benefit from the M&A merry-go-round. At Mutares, buying and selling companies is part of everyday business. With potential takeover targets such as LAURION Mineral Exploration and Evotec, investors can acquire attractively valued companies and simply wait for a strategic buyer to make a move. LAURION Mineral Exploration controls a high-quality asset whose value should continue to grow through ongoing drilling programs and further development.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author



    Related comments:

    Commented by Nico Popp on May 12th, 2026 | 09:10 CEST

    Biotech and the Efficiency Revolution: Why the Final Mile Matters Most for Novartis, BioNTech, and BioNxt

    • Biotechnology
    • Biotech
    • patents

    While biotech investors long believed that only the discovery of an entirely new molecule could pave the way for a billion-dollar exit, the current market reality paints a far more nuanced picture. Savvy investors and industry analysts are increasingly recognizing that the true bottleneck in modern medicine is no longer the discovery of active ingredients alone. Instead, the strategic focus is shifting toward bioavailability, targeted drug delivery, and improved patient compliance. This transformation is being accelerated by the looming patent cliff, which threatens the pharmaceutical industry with combined annual peak revenues of several hundred billion US dollars by 2030. We take a closer look at the market and highlight emerging opportunities.

    Read

    Commented by Carsten Mainitz on May 12th, 2026 | 07:40 CEST

    Almonty Industries: No investor should miss out on this strategic investment!

    • Mining
    • Tungsten
    • CriticalMetals
    • Defense
    • hightech
    • AI
    • semiconductor
    • geopolitics

    As the saying goes, political stock markets are short-lived. But as we all know, there are no rules without exceptions. Nervousness on the stock markets has now subsided again. However, the Iran conflict and its associated economic repercussions cannot be ignored. How can investors position themselves in this environment? Commodity producers in general, and particularly those producing critical raw materials, will be among the winners, regardless of how the stock markets perform in the coming quarters. And this is where Almonty Industries stands out. The company is one of the leading producers of the critical raw material tungsten. Tungsten has become indispensable across several industries and is virtually irreplaceable, and the market has undergone a fundamental shift. Prices are surging, and Almonty Industries is the only source of Western production outside of China, which dominates 80% of the market. Almonty's enormous geopolitical significance is one of the many reasons to buy the stock, which analysts believe has significant upside potential.

    Read

    Commented by Matthias Schomber on May 12th, 2026 | 07:30 CEST

    China's Stranglehold and the Achilles' Heel of Military Build-Up: The Thriller Involving Rheinmetall, RENK, and Antimony Resources

    • Mining
    • antimony
    • CriticalMetals
    • Defense
    • hightech

    Created and published on behalf of Antimony Resources Corp.

    The world is arming itself, and on the stock market, the big names in the defence industry celebrated an unprecedented rally. But recently, things have been going downhill for Rheinmetall & Co. on the stock market! Behind the gleaming facades of factory buildings and the impressive order books of Rheinmetall and RENK lies an uncomfortable truth. The massive production of ammunition and high-performance propulsion systems also depends on an almost forgotten raw material that China controls almost single-handedly. Antimony is the secret link that determines victory or defeat in industrial logistics. While industry giants search for stable sources, a Canadian exploration company is emerging that could close a strategic gap in the West. It is a game with extremely high stakes, where geopolitics, military necessity, and enormous profit opportunities collide head-on. When might share prices for Rheinmetall & Co. start rising again?

    Read